The final, formatted version of the article will be published soon.
REVIEW article
Front. Cell Dev. Biol.
Sec. Cancer Cell Biology
Volume 12 - 2024 |
doi: 10.3389/fcell.2024.1453630
New Insight in Immunotherapy and Combine Therapy in Colorectal Cancer
Provisionally accepted- 1 Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
- 2 Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, Shanghai, Beijing Municipality, China
The advent of immune checkpoint inhibitors (ICIs) in colorectal cancer (CRC) treatment marks a major breakthrough. These therapies have proven safer and more effective than traditional radiotherapy and targeted treatments. Immunotherapies like pembrolizumab, nivolumab, and ipilimumab have pioneered new treatment avenues, potentially improving patient outcomes and quality of life. Additionally, advances in immunotherapy have prompted detailed research into CRC therapies, especially those integrating ICIs with conventional treatments, providing new hope for patients and shaping future research and practice. This review delves into the mechanisms of various ICIs and evaluates their therapeutic potential when combined with radiotherapy, chemotherapy, and targeted therapies in clinical settings. It also sheds light on the current application and research involving ICIs in CRC treatment.
Keywords: immunomodulatory, ICIS, Radiotherapy, chemotherapy, combination therapy, colorectal cancer
Received: 24 Jun 2024; Accepted: 18 Dec 2024.
Copyright: © 2024 Ji, Jia, Liu, Yu, Wen, Zhang, Peng, Man, Tian, Wang, Ling, Zhang, Zhou, Liu and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zixuan Liu, Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, Shanghai, Beijing Municipality, China
Tianshuai Zhang, Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, Shanghai, Beijing Municipality, China
Wenjiang Man, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
Can Wang, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
Qianlong Ling, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
Leqi Zhou, Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, Shanghai, Beijing Municipality, China
Mulin Liu, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
Bing Zhu, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.